FDA approves first RAS-targeted pancreatic cancer drug from Revolution Medicines
On August 26, 2026, the U.S. Food and Drug Administration approved Rasonque daraxonrasib, a groundbreaking oral therapy for adults with metastatic pancreatic cancer who have previously undergone chemotherapy. Developed by Revolution Medicines (RVMD), this is the first broad RAS-targeted drug to reach market after decades of failed attempts targeting the protein responsible for over 90% of pancreatic tumors. In clinical trials, Rasonque nearly doubled median overall survival from 6.7 months with standard chemotherapy to 13.2 months and reduced the risk of death by 60%. The FDA fast-tracked its approval under a national priority voucher program due to the urgent unmet medical need for pancreatic cancer treatments. The drug’s commercial launch marks Revolution Medicines’ transition from a clinical-stage company with $3.9 billion in cash reserves to one selling an approved product, priced at $39,800 per 30-day supply.
Tickers: $RVMD